Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hydroxychloroquine Clear all
Active, not recruiting Phase 2 Interventional Results available

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

NCT03032406
View directory record Official record
Conditions
Breast Cancer Stage IIB
Interventions
Hydroxychloroquine, Everolimus
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 16, 2026, 4:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

NCT00977470
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib, Hydroxychloroquine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 16, 2026, 4:30 PM EDT
Withdrawn Phase 2 Interventional

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

NCT04363866
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 1 Interventional

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

NCT01144169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Hydroxychloroquine (HC)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 16, 2026, 4:30 PM EDT
Active, not recruiting Phase 1 Interventional

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

NCT01480154
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

NCT04353037
View directory record Official record
Conditions
Coronavirus, Corona Virus Infection
Interventions
Group 1 HCQ, Group 2 Placebo
Drug
Lead sponsor
UnitedHealth Group
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 16, 2026, 4:30 PM EDT
Completed No phase listed Observational

Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus

NCT05922722
View directory record Official record
Conditions
Lupus
Interventions
Decision-making tool, Questionnaire
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315
View directory record Official record
Conditions
Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions
Hydroxychloroquine, Matching Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

NCT02603146
View directory record Official record
Conditions
Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Interventions
Hydroxychloroquine, HCQ Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

NCT04566133
View directory record Official record
Conditions
Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions
Trametinib, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

NCT03428945
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 16, 2026, 4:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine

NCT04691505
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Hydroxychloroquine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
133,553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer

NCT01273805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 16, 2026, 4:30 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

NCT04120883
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 16, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 16, 2026, 4:30 PM EDT